期刊
VACCINE
卷 39, 期 48, 页码 7001-7011出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2021.10.066
关键词
SARS-CoV-2; Trimeric spike protein; Subunit vaccine
The researchers have developed a recombinant vaccine against SARS-CoV-2, which showed strong immunogenicity in animal studies, inducing robust antibody responses and T cell responses. The vaccine also demonstrated cross-neutralization activity against various variants, significantly reducing viral loads and lung inflammation.
COVID-19 pandemic has severely impacted the public health and social economy worldwide. A safe, effective, and affordable vaccine against SARS-CoV-2 infections/diseases is urgently needed. We have been developing a recombinant vaccine based on a prefusion-stabilized spike trimer of SARS-CoV-2 and formulated with aluminium hydroxide and CpG 7909. The spike protein was expressed in Chinese hamster ovary (CHO) cells, purified, and prepared as a stable formulation with the dual adjuvant. Immunogenicity studies showed that candidate vaccines elicited robust neutralizing antibody responses and substantial CD4+ T cell responses in both mice and non-human primates. And vaccine-induced neutralizing antibodies persisted at high level for at least 6 months. Challenge studies demonstrated that candidate vaccine reduced the viral loads and inflammation in the lungs of SARS-CoV-2 infected golden Syrian hamsters significantly. In addition, the vaccine-induced antibodies showed cross-neutralization activity against B.1.1.7 and B.1.351 variants. These data suggest candidate vaccine is efficacious in preventing SARS-CoV-2 infections and associated pneumonia, thereby justifying ongoing phase I/II clinical studies in China (NCT04982068 and NCT04990544). (c) 2021 Shanghai Zerun Biotechnology, Co., Ltd. Published by Elsevier Ltd. This is an open access article
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据